[A12-20] Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 02.04.2013
Commission awarded on 18.12.2012 by the Federal Joint Committee (G-BA).
Prevention and screening, Head and nerves
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A14-28||Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)||Commission completed|
|A11-30||Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)||Commission completed|